XPH vs. JAGLX
Compare and contrast key facts about SPDR S&P Pharmaceuticals ETF (XPH) and Janus Henderson Global Life Sciences Fund Class T (JAGLX).
XPH is a passively managed fund by State Street that tracks the performance of the S&P Pharmaceuticals Select Industry Index. It was launched on Jun 19, 2006. JAGLX is an actively managed fund by Janus Henderson. It was launched on Dec 31, 1998.
Performance
XPH vs. JAGLX - Performance Comparison
Loading graphics...
XPH vs. JAGLX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
XPH SPDR S&P Pharmaceuticals ETF | -2.19% | 31.60% | 4.94% | 2.97% | -9.83% | -10.54% | 14.68% | 25.61% | -15.32% | 12.05% |
JAGLX Janus Henderson Global Life Sciences Fund Class T | -3.75% | 24.72% | 8.50% | 7.41% | -2.79% | 6.66% | 25.52% | 29.12% | 4.05% | 22.13% |
Returns By Period
In the year-to-date period, XPH achieves a -2.19% return, which is significantly higher than JAGLX's -3.75% return. Over the past 10 years, XPH has underperformed JAGLX with an annualized return of 3.94%, while JAGLX has yielded a comparatively higher 11.55% annualized return.
XPH
- 1D
- 1.16%
- 1M
- -4.82%
- YTD
- -2.19%
- 6M
- 13.09%
- 1Y
- 30.74%
- 3Y*
- 11.47%
- 5Y*
- 3.03%
- 10Y*
- 3.94%
JAGLX
- 1D
- 3.08%
- 1M
- -5.56%
- YTD
- -3.75%
- 6M
- 11.82%
- 1Y
- 21.58%
- 3Y*
- 12.33%
- 5Y*
- 8.24%
- 10Y*
- 11.55%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
XPH vs. JAGLX - Expense Ratio Comparison
XPH has a 0.35% expense ratio, which is lower than JAGLX's 0.92% expense ratio.
Return for Risk
XPH vs. JAGLX — Risk / Return Rank
XPH
JAGLX
XPH vs. JAGLX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Pharmaceuticals ETF (XPH) and Janus Henderson Global Life Sciences Fund Class T (JAGLX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| XPH | JAGLX | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.28 | 1.06 | +0.21 |
Sortino ratioReturn per unit of downside risk | 1.80 | 1.53 | +0.27 |
Omega ratioGain probability vs. loss probability | 1.23 | 1.20 | +0.03 |
Calmar ratioReturn relative to maximum drawdown | 1.97 | 1.78 | +0.19 |
Martin ratioReturn relative to average drawdown | 6.54 | 4.92 | +1.62 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| XPH | JAGLX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.28 | 1.06 | +0.21 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.15 | 0.53 | -0.38 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.18 | 0.66 | -0.49 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.38 | 0.58 | -0.20 |
Correlation
The correlation between XPH and JAGLX is 0.83, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
XPH vs. JAGLX - Dividend Comparison
XPH's dividend yield for the trailing twelve months is around 0.68%, less than JAGLX's 4.70% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
XPH SPDR S&P Pharmaceuticals ETF | 0.68% | 0.83% | 1.58% | 1.28% | 1.64% | 0.95% | 0.47% | 0.64% | 0.65% | 0.67% | 0.63% | 7.15% |
JAGLX Janus Henderson Global Life Sciences Fund Class T | 4.70% | 4.53% | 10.98% | 4.22% | 0.14% | 9.78% | 7.75% | 6.17% | 13.38% | 0.89% | 1.13% | 9.09% |
Drawdowns
XPH vs. JAGLX - Drawdown Comparison
The maximum XPH drawdown since its inception was -48.03%, smaller than the maximum JAGLX drawdown of -58.96%. Use the drawdown chart below to compare losses from any high point for XPH and JAGLX.
Loading graphics...
Drawdown Indicators
| XPH | JAGLX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -48.03% | -58.96% | +10.93% |
Max Drawdown (1Y)Largest decline over 1 year | -13.15% | -9.71% | -3.44% |
Max Drawdown (5Y)Largest decline over 5 years | -31.63% | -22.25% | -9.38% |
Max Drawdown (10Y)Largest decline over 10 years | -35.97% | -27.38% | -8.59% |
Current DrawdownCurrent decline from peak | -6.21% | -6.64% | +0.43% |
Average DrawdownAverage peak-to-trough decline | -17.37% | -17.51% | +0.14% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.96% | 3.63% | +0.33% |
Volatility
XPH vs. JAGLX - Volatility Comparison
SPDR S&P Pharmaceuticals ETF (XPH) has a higher volatility of 9.05% compared to Janus Henderson Global Life Sciences Fund Class T (JAGLX) at 5.99%. This indicates that XPH's price experiences larger fluctuations and is considered to be riskier than JAGLX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| XPH | JAGLX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.05% | 5.99% | +3.06% |
Volatility (6M)Calculated over the trailing 6-month period | 16.40% | 10.63% | +5.77% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.50% | 17.86% | +6.64% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.57% | 15.76% | +4.81% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.22% | 17.45% | +4.77% |